Please provide your email address to receive an email when new articles are posted on . Mavacamten (Bristol Myers Squibb) also improved symptoms, biomarker levels and quality of life metrics compared ...
Please provide your email address to receive an email when new articles are posted on . In patients with obstructive hypertrophic cardiomyopathy, septal reduction therapy was associated with reduced ...
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced results from the Phase 3 VALOR-HCM study, which showed the addition of mavacamten, an investigational, first-in-class ...
—Surgical ventricular septal reduction or alcohol septal ablation therapy? A study in France tapped a nationwide database to better describe and compare the safety of the 2 septal reduction therapy ...
WASHINGTON – Treatment with investigational mavacamten allowed patients with advanced obstructive hypertrophic cardiomyopathy (oHCM) to avoid septal reduction therapies (SRT), a researcher reported.
PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that VALOR-HCM, the Phase 3 randomized, double-blind, placebo-controlled study evaluating mavacamten in adults with ...
Treatment with a novel myosin-inhibiting agent may improve symptoms and hemodynamics enough in patients with obstructive hypertrophic cardiomyopathy (OHCM) so that they can avoid or at least delay ...
Panel A shows a cross-section of a normal heart (top) and an endomyocardial biopsy sample from a normal heart (bottom; with hematoxylin and eosin staining) that shows normal histologic characteristics ...
WASHINGTON, DC (UPDATED)—Among patients with obstructive hypertrophic cardiomyopathy (HCM) who are candidates for surgical or interventional septal reduction therapy (SRT) despite being on maximally ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results